Abbonarsi

Elevated plasma galectin-3 is associated with near-term rehospitalization in heart failure: A pooled analysis of 3 clinical trials - 31/05/14

Doi : 10.1016/j.ahj.2014.02.011 
Wouter C. Meijers, MD a, James L. Januzzi, MD b, Christopher deFilippi, MD c, Aram S. Adourian, PhD d, Sanjiv J. Shah, MD e, Dirk J. van Veldhuisen, MD, PhD a, Rudolf A. de Boer, MD, PhD a,
a University of Groningen, Medical Center Groningen, Department of Cardiology, Groningen, The Netherlands 
b Massachusetts General Hospital, Division of Cardiology, Boston, MA 
c University of Maryland School of Medicine, Department of Medicine, Baltimore, MD 
d BG Medicine, Waltham, MA 
e Northwestern University Feinberg School of Medicine, Division of Cardiology, Chicago, IL 

Reprint requests: Rudolf A. de Boer, MD, PhD, Department of Cardiology, University of Groningen, PO Box 30.001, 9700 RB, Groningen, The Netherlands.

Riassunto

Background

Rehospitalization is a major cause for heart failure (HF)–related morbidity and is associated with considerable loss of quality of life and costs. The rate of unplanned rehospitalization in patients with HF is unacceptably high; current risk stratification to identify patients at risk for rehospitalization is inadequate. We evaluated whether measurement of galectin-3 would be helpful in identifying patients at such risk.

Methods

We analyzed pooled data from patients (n = 902) enrolled in 3 cohorts (COACH, n = 592; PRIDE, n = 181; and UMD H-23258, n = 129) originally admitted because of HF. Mean patient age was between 61.6 and 72.9 years across the cohorts, with a wide range of left ventricular ejection fraction. Galectin-3 levels were measured during index admission. We used fixed and random-effects models, as well as continuous and categorical reclassification statistics to assess the association of baseline galectin-3 levels with risk of postdischarge rehospitalization at different time points and the composite end point all-cause mortality and rehospitalization.

Results

Compared with patients with galectin-3 concentrations less than 17.8 ng/mL, those with results exceeding this value were significantly more likely to be rehospitalized for HF at 30, 60, 90, and 120 days after discharge, with odds ratios (ORs) of 2.80 (95% CI 1.41-5.57), 2.61 (95% CI 1.46-4.65), 3.01 (95% CI 1.79-5.05), and 2.79 (95% CI 1.75-4.45), respectively. After adjustment for age, gender, New York Heart Association class, renal function (estimated glomerular filtration rate), left ventricular ejection fraction, and B-type natriuretic peptide, galectin-3 remained an independent predictor of HF rehospitalization. The addition of galectin-3 to risk models significantly reclassified patient risk of postdischarge rehospitalization and fatal event at each time point (continuous net reclassification improvement at 30 days of +42.6% [95% CI +19.9%-65.4%], P < .001).

Conclusions

Among patients hospitalized for HF, plasma galectin-3 concentration is useful for the prediction of near-term rehospitalization.

Il testo completo di questo articolo è disponibile in PDF.

Mappa


© 2014  The Author. Pubblicato da Elsevier Masson SAS. Tutti i diritti riservati.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 167 - N° 6

P. 853 - Giugno 2014 Ritorno al numero
Articolo precedente Articolo precedente
  • Prevalence and predictors of nonobstructive coronary artery disease identified with coronary angiography in contemporary clinical practice
  • Manesh R. Patel, David Dai, Adrian F. Hernandez, Pamela S. Douglas, John Messenger, Kirk N. Garratt, Thomas M. Maddox, Eric D. Peterson, Matthew T. Roe
| Articolo seguente Articolo seguente
  • Association between alcohol consumption and systolic ventricular function: A population-based study
  • Haroon Yousaf, Richard J. Rodeheffer, Timothy E. Paterick, Zain Ashary, Mirza Nubair Ahmad, Khawaja Afzal Ammar

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.

Già abbonato a @@106933@@ rivista ?

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2025 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.